The study sought to assess feasibility, safety, and potential efficacy of a novel implantable extra-aortic counterpulsation system (C-Pulse) in functional class III and ambulatory functional class IV heart failure (HF) patients.
F
unctional status and quality of life (QoL) remain poor for at least 30% to 40% of chronic heart failure patients, who remain categorized in New York Heart Association (NYHA) functional class III or IV despite optimal evidence-based drug and electrophysiological device therapies (1) . These patients with advanced heart failure are also at the greatest risk for heart failure-related hospitalization and mortality, with a 1-year mortality rate of at least 10% to 15% (2) (3) (4) . While therapies such as cardiac transplanta- One emerging approach to these patients is through the use of chronic ambulatory aortic counterpulsation (7) (8) (9) . Aortic counterpulsation is a wellestablished mode of circulatory support that works by reducing left ventricular after-load during systole and augmenting blood pressure and systemic and coronary perfusion during diastole (10) (11) (12) . While the application of aortic counterpulsation in acutely ill patients involves the use of an intra-aortic system (the intra-aortic balloon pump), implantable intraand extra-aortic counterpulsation systems have been developed for chronic ambulatory use (13) (14) (15) (16) . One such system, the C-Pulse System (Sunshine Heart, Inc., Eden Prairie, Minnesota), includes a novel implantable, nonobligatory, non-blood contacting counterpulsation heart assist pump developed for minimally invasive implantation without the need for cardiopulmonary bypass (15,16). The present study was designed to further assess the feasibility, safety, and potential efficacy of the C-Pulse System in the intended population. 
Abraham et al. were discharged from the hospital once heart failure medications were re-established and the patients were ambulatory and able to demonstrate the ability to care for the exit site and manage the driver.
Patients were scheduled to be seen by the heart failure clinician-investigator and study coordinator at 1, 3, 6, and 12 months post-implant. During the primary Abraham et al.
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period of follow-up (the first 6 months), the C-Pulse
System was intended to be used at least 20 h per day.
The non-blood contacting feature of the C-Pulse System allows the device to be intermittently turned off as tolerated. This enables the patient to be "untethered" Values are mean AE SD (range), % (n/N), or mean AE SD (n) (minimum, maximum).
ALT ¼ aspartate aminotransferase; AST ¼ alanine aminotransferase; NYHA ¼ New York Heart Association.
Baseline and follow-up data were used to assess differences in NYHA functional class, QoL, and exer- Table 1 . As required by protocol, all patients were on stable optimal medical therapy. All had an implantable cardioverter-defibrillator, and 45% had a combined biventricular pacer-implantable cardioverter-defibrillator. Characteristics of the implant procedures are detailed in Table 2. SAFETY. In general, the implant procedure was safe. There were no operative deaths (i.e., there was no mortality within 30 days of the implant procedure). Values are mean AE SD (n), median (minimum, maximum) or % (n/N).
ICU ¼ intensive care unit. One-year survival was 85%. Table 3 presents the primary safety endpoint analysis at 6 and 12 months.
The composite device-related adverse event rate through 6 months, as classified by the Clinical Events
Committee, was 50%. This result was influenced by the exit site infection rate of 40%. Between 6 months and 12 months, there were no additional patients with device-related serious adverse events.
EFFICACY. Table 4 presents the efficacy analysis at 6 and 12 months. Significant improvements were noted in NYHA functional class at both 6 and 12 months. The Kansas City Cardiomyopathy Questionnaire score also significantly improved at 6 and 12 months. The 6MWD showed a trend toward improvement at 6 months and significantly improved at 12 months.
There was no improvement in pVO 2 at 6 months.
There was a low rate of heart failure hospitalization in these patients. Over 12 months, 3 of the 20 implanted patients (15%) had 5 Clinical Events Committee-adjudicated heart failure hospitalizations.
Few of these occurred during active therapy, and C-Pulse System nonadherence appeared to be related to most of these heart failure hospitalizations; specifically, 2 of these 3 patients were nonadherent (utilizing the system <30% of the time) in the weeks before their heart failure hospitalizations. Over 12 months, there were 40 non-heart failure related hospitalizations in 19 patients. Of these, 10 were related to PIL issues in 9 patients (45%) From the safety standpoint, the composite adverse event assessment was dominated by the incidence of The present feasibility study suggests that the CPulse System may be safe in patients with moderate to severe heart failure. It also offers preliminary insight into the potential effectiveness of the therapy in these patients. On the basis of review of the feasibility study data, a prospective, randomized,
controlled trial designed to demonstrate and extend these observations was approved by the U.S. Food and Drug Administration in November 2012 and is currently underway.
